JNJ250117P141000
- 0.34
- -0.94-73.44%
Johnson & Johnson Newsroom
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Equities Mixed Intraday as Markets Await Bank Earnings, Inflation Data
Sector Update: Health Care
Dean Omar Branham Shirley's Partners Named to List of 500 Leading Lawyers in America
UnitedHealth, Caterpillar Share Gains Contribute To Dow's 240-Point Climb
US Equity Indexes Mixed as Magnificent-7 Stocks Decline Amid Gains in Treasury Yields
Is Johnson & Johnson (JNJ) the Most Reliable Dividend Stock to Buy According to Hedge Funds?
Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel
The Top and Bottom Contributors to S&P 500's Q4 EPS Growth
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
Intra-Cellular surged nearly 35%! Johnson & Johnson plans to spend $10 billion to acquire the company, marking the largest Biotechnology merger in nearly two years!
This is the largest Trade in the biotechnology Industry in nearly two years, and it is also the first Biomedical merger exceeding 10 billion dollars since 2024, indicating a resurgence in merger and acquisition activities in the Medical Care sector. Goldman Sachs stated that the potential financing capacity of large Biopharmaceutical companies is at least 500 billion dollars, providing significant operational space for R&D investment, merger expansion, and more.
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal
US stock outlook | Wall Street begins to discuss the possibility of interest rate hikes! The three major index futures collectively weakened; Intra-Cellular surged nearly 35% in pre-market trading! It will be acquired by Johnson & Johnson for billions.
Tesla fell 3% before the market opened, as the largest Retirement Fund in Europe liquidated its shares; the yield on the 10-year US Treasury is aiming for 5%! The Global bond market is in turmoil.
Johnson & Johnson (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for sale in the domestic market.
Johnson & Johnson (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for sale in the domestic market.
Top Premarket Gainers
Express News | Oric Pharmaceuticals Inc - to Initiate Phase 1B Trial for Oric-114 in Q1 2025
Express News | Oric Pharmaceuticals Inc - to Conduct and Sponsor Trial; J&J to Provide Sc Amivantamab
Express News | Oric Pharmaceuticals Inc - Enters Supply Agreement With Janssen to Evaluate Oric-114
Express News | Intra-Cellular Therapies: Upon Termination of Deal, Under Specified Circumstances, Co to Pay Johnson & Johnson Termination Fee of $475.5 Mln